Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RAD52 | P43351 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.41 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723844 | 0.89 | MAPT (0.59) | HSD17B10S1PR1MAPTKDM4ERAD52 | |
| SCHEMBL18872669 | 0.89 | LMNA (0.59) | SLC6A9MAPTLMNAALDH1A1SIGMAR1 | |
| SCHEMBL16656260 | 0.89 | LMNA (0.59) | SLC6A9MAPTLMNAALDH1A1SIGMAR1 | |
| SCHEMBL8655258 | 0.89 | LMNA (0.59) | SLC6A9MAPTLMNAALDH1A1SIGMAR1 | |
| SCHEMBL6550220 | 0.86 | SIGMAR1 (0.60) | S1PR1MAPTSMN1; SMN2ALDH1A1SIGMAR1 | |
| SCHEMBL23876498 | 0.85 | SLC6A9 (0.39) | SLC6A9HSD17B10S1PR1MAPTKDM4E | |
| SCHEMBL15499796 | 0.85 | NPC1 (0.56) | MAPTKDM4ERAD52SMN1; SMN2GAA | |
| SCHEMBL17076742 | 0.83 | MAPT (0.53) | HSD17B10S1PR1MAPTKDM4ERAD52 | |
| SCHEMBL15652766 | 0.82 | SLC18A3 (0.48) | S1PR1SIGMAR1 | |
| SCHEMBL3897416 | 0.82 | ALDH1A1 (0.64) | KDM4ELMNAALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911457-B2 | Imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions. | CARBOMER, INC. (US) | 2005-06-28 | — | — | US | claimed |
| US-20030207823-A1 | Novel diabetes imaging probes | CARBOMER, INC. | 2003-11-06 | — | — | US | claimed |
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| EP-2433963-A1 | Receptor (SSTR2)-selective somatostatin antagonists | The Salk Institute for Biological Studies (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110269683-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | UNIVERSITY HOSPITAL BASEL | 2011-11-03 | — | — | US | disclosed |
| EP-2383289-A1 | Receptor (SSTR2)-selective somatostatin antagonists | The Salk Institute for Biological Studies (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7960342-B2 | Side effect reduction; block receptor function so they can be used in therapy; labeled with radioactive iodine; drug screening | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2011-06-14 | — | — | US | disclosed |
| US-7192570-B2 | Compositions of somatostatin analogues | UNIVERSITY OF BERN (CH) | 2007-03-20 | — | — | US | disclosed |
| EP-1419178-B1 | SOMATOSTATIN ANALOGUES AND THEIR USE SOMATOSTATIN ANALOGUES BINDING TO ALL SOMATOSTATIN RECEPTOR AND THEIR USE | UNIV BERN (CH) | 2006-05-31 | — | — | EP | disclosed |
| US-7048907-B2 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | BIOPHYSICS ASSAY LABORATORY, INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20060067881-A1 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | BIOPHYSICS ASSAY LABORATORY, INC. | 2006-03-30 | — | — | US | disclosed |
| US-6911457-B2 | Imaging probes and methods for using the probes in diagnostic imaging processes and other imaging processes to determine physiological functions. | CARBOMER, INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | UNIVERSITY OF BERN (CH) | 2004-12-02 | — | — | US | disclosed |
| US-20030207823-A1 | Novel diabetes imaging probes | CARBOMER, INC. | 2003-11-06 | — | — | US | disclosed |
| US-20030059368-A1 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | BIOPAL, INC. | 2003-03-27 | — | — | US | disclosed |
| EP-1283216-A1 | Somatostatin analogues binding to all somatostatin receptor subtypes and their use | Mallinckrodt Inc. (US) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | SLC6A9 2411/4885HSD17B10 1848/4885S1PR1 182/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | SLC6A9 2411/4885HSD17B10 1848/4885S1PR1 182/4885 |
| US-20040242842-A1 | Somatostatin analogues and their use somatostatin analogues binding to all somatostatin receptor and their use | SSTR5, NPY5R, GLP1R | SLC6A9 1343/4885HSD17B10 2830/4885S1PR1 2617/4885 |
| US-20110269683-A1 | RECEPTOR(SSTR2)-SELECTIVE SOMATOSTATIN ANTAGONISTS | SSTR5, SSTR4, SSTR3 | SLC6A9 1251/4885HSD17B10 2885/4885S1PR1 165/4885 |
| US-20030207823-A1 | Novel diabetes imaging probes | IAPP, GPR119, DPP4 | SLC6A9 1863/4885HSD17B10 633/4885S1PR1 837/4885 |
| US-20060067881-A1 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | ATP6V1B1, REN, GLS | SLC6A9 595/4885HSD17B10 4172/4885S1PR1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.